马伐卡坦:肥厚性心肌病患者鼻中隔缩小治疗的替代方案。

IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart International Pub Date : 2023-01-01 DOI:10.17925/HI.2023.17.1.2

Milind Y Desai, Adel Hajj Ali

{"title":"马伐卡坦:肥厚性心肌病患者鼻中隔缩小治疗的替代方案。","authors":"Milind Y Desai, Adel Hajj Ali","doi":"10.17925/HI.2023.17.1.2","DOIUrl":null,"url":null,"abstract":"Hypertrophic cardiomyopathy (HCM) is a common heridetary cardiac disorder characterized by a wide range of symptoms. The pharmacological treatment of HCM is currently limited to beta blockers, non-dihydropyridine calcium channel blockers and disopyramide. Mavacamten is a novel cardiac myosin inhibitor, which was recently added to the limited pharmacological list of treatment options for HCM. This editorial elaborates on current evidence evaluating the use of mavacamten in patients with symptomatic obstructive HCM, comments on its current use and its expanded potential applications in the future.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"17 1","pages":"2-4"},"PeriodicalIF":1.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339467/pdf/touchcardio-17-1-2.pdf","citationCount":"0","resultStr":"{\"title\":\"Mavacamten, an Alternative to Septal Reduction Therapy for Patients with Hypertrophic Cardiomyopathy.\",\"authors\":\"Milind Y Desai, Adel Hajj Ali\",\"doi\":\"10.17925/HI.2023.17.1.2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hypertrophic cardiomyopathy (HCM) is a common heridetary cardiac disorder characterized by a wide range of symptoms. The pharmacological treatment of HCM is currently limited to beta blockers, non-dihydropyridine calcium channel blockers and disopyramide. Mavacamten is a novel cardiac myosin inhibitor, which was recently added to the limited pharmacological list of treatment options for HCM. This editorial elaborates on current evidence evaluating the use of mavacamten in patients with symptomatic obstructive HCM, comments on its current use and its expanded potential applications in the future.\",\"PeriodicalId\":12836,\"journal\":{\"name\":\"Heart International\",\"volume\":\"17 1\",\"pages\":\"2-4\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339467/pdf/touchcardio-17-1-2.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Heart International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17925/HI.2023.17.1.2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/HI.2023.17.1.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

肥厚性心肌病(HCM)是一种常见的遗传性心脏疾病，其症状范围广泛。HCM的药物治疗目前仅限于-受体阻滞剂、非二氢吡啶钙通道阻滞剂和二酰胺。Mavacamten是一种新型心肌肌球蛋白抑制剂，最近被添加到HCM的有限药物治疗选择列表中。这篇社论详细阐述了目前评估马伐卡坦在症状性阻塞性HCM患者中的应用的证据，并对其目前的使用和未来扩大的潜在应用进行了评论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Mavacamten, an Alternative to Septal Reduction Therapy for Patients with Hypertrophic Cardiomyopathy.

Hypertrophic cardiomyopathy (HCM) is a common heridetary cardiac disorder characterized by a wide range of symptoms. The pharmacological treatment of HCM is currently limited to beta blockers, non-dihydropyridine calcium channel blockers and disopyramide. Mavacamten is a novel cardiac myosin inhibitor, which was recently added to the limited pharmacological list of treatment options for HCM. This editorial elaborates on current evidence evaluating the use of mavacamten in patients with symptomatic obstructive HCM, comments on its current use and its expanded potential applications in the future.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Heart International Medicine-Cardiology and Cardiovascular Medicine

CiteScore

0.90

自引率

0.00%

发文量

审稿时长

7 weeks